Sweden Pharmaceuticals & Healthcare Report Q2 2015
Headline Expenditure Projections
Risk/Reward Index : We continue to view Sweden as a moderately attractive regional market. On the positive side, factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this small market of fewer than 10mn people.
- Pharmaceuticals: SEK36.28bn (USD5.70bn) in 2013 to SEK36.41bn (USD5.36bn) in 2014; +0.38% in local currency terms and -5.9% in US dollar terms.
- Healthcare: SEK351.16bn (USD55.18bn) in 2013 to SEK356.95bn (USD52.56bn) in 2014; +1.6% in local currency terms and -4.7% in US dollar terms.
Key Trends And Developments
Sweden has the best healthcare system to deal with diabetes of all the EU member states, including Norway and Switzerland, as it has a better national registry, according to the 2014 Euro Diabetes Index launched in Vienna. Sweden was followed by the Netherlands, Denmark and the UK, while Bulgaria, Lithuania and Estonia scored lowest. The analysis, which came from the Health Consumer Powerhouse (HCP), was based on 28 defined indicators and areas, including prevention, case finding, range and reach of services, access to treatment and care, procedures and outcomes. Sweden only needs to improve its prevention under 'Exercise in compulsory school', according to the HCP.
About 850,000 false prescriptions are corrected by pharmacies every year in Sweden,...
The Sweden Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Sweden Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sweden pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Sweden, to test other views - a key input for successful budgeting and strategic business planning in the Swedish pharmaceutical and healthcare market.
- Target business opportunities and risks in the Swedish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sweden.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
BMIs Pharmaceuticals and Healthcare Risk Reward Index
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMIs Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the markets risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMIs industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.
Declining government reimbursement for prescription medicines does not bode well for innovative drugmakers selling their products in Sweden, particularly as the government is the primary purchaser of pharmaceuticals. Furthermore, over the long term, pushing costs onto a population with fewer young people to financially support the elderly will ultimately work to reduce the consumption of higher-value innovative pharmaceuticals.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
OTC Medicine Market Forecast
Table: OTC Sales by Therapeutic Group At Retail Prices, 2009-2010 (SEKmn)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2010-2018)
Pharmaceutical Trade Forecast
Table: Parallel Imported Pharmaceutical Market at Wholesale Prices, 1997-2010
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
GDP By Expenditure
Table: GDP By Expenditure (Sweden 2011-2018)
Industry Risk Reward Ratings
Western Europe Risk/Reward Index
Sweden Risk/Reward Index
Industry Trends And Developments
Research And Development
Table: Drug Development Member Companies of SwedenBIO, 2011
Clinical Trials Sector
Intellectual Property Regime
Table: Price Decline For Off-Patent Drugs
Recent Pricing Developments
Pharmaceuticals Manufacturing Sector
Table: Top Sweden-Based Pharmaceutical Companies By Market Capitalisation
Table: Leading Pharmaceutical Companies By Sales At Wholesale Prices, 2007-2010 (SEKmn)
Table: Pharmaceutical Sales By Leading Pharmaceutical Group At Wholesale Prices, 2007-2010 (SEKmn)
Pharmaceutical Industry Developments
Table: Drug Retail Establishments by Type, 2006-2010
Swedish Orphan Biovitrum (SOBI)
Merck & Co
Table: Sweden's Population By Age Group, 1990-2020 ('000)
Table: Sweden's Population By Age Group, 1990-2020 (% of total)
Table: Sweden's Key Population Ratios, 1990-2020
Table: Sweden's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Table: Pharmaceutical Risk/Reward Index Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it